Belite Bio Inc (BLTE) Stock Price & News

Analyst	Recommendation	Action	Price target	Projected	Date
Graig Suvannavejh Mizuho Securities	Buy	Maintained	$234.00	+49.9%	09/09/2026
Yi Chen H.C. Wainwright	Buy	Reiterated	$245.00	+57%	09/09/2026
Whitney Ijem Canaccord Genuity	Buy	Initiated	$303.00	+94.1%	09/04/2026
Tazeen Ahmad Bank of America Securities	Buy	Maintained	$200.00	+28.1%	09/02/2026
Judah Frommer Morgan Stanley	Buy	Maintained	$206.00	+32%	08/17/2026
Michael Okunewitch Maxim Group	Buy	Maintained	$200.00	+28.1%	08/14/2026
Steven Seedhouse Cantor Fitzgerald	Buy	Maintained	$270.00	+73%	08/14/2026
Bruce Jackson Benchmark Co.	Buy	Maintained	$217.00	+39%	03/03/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	10.31M	14.62M	15.66M	18.21M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	12.71M	13.45M	17.02M	16.69M
Operating expense	23.02M	28.08M	32.68M	34.91M
Total operating expenses	23.02M	28.08M	32.68M	34.91M
Operating income	-23.02M	-28.08M	-32.68M	-34.91M
Other non operating income	-2.14M	-417.00K	5.75M	6.55M
EBT including unusual items	-21.69M	-25.32M	-26.94M	-28.36M
EBT excluding unusual items	-21.69M	-25.32M	-26.94M	-28.36M
Income tax expense	-	-	-	55.00K
Effective tax rate	-	-	-	-0.19%
Other operating expenses	-	-	-	-
Net income	-21.69M	-25.32M	-26.94M	-28.41M
Net profit margin	-	-	-	-
Earnings per share	-0.65	-0.70	-0.68	-0.70
Interest and investment income	3.47M	3.17M	-	-
Interest expense	-	-2.00K	-	-
Net interest expenses	3.47M	3.17M	-	-
Depreciation and amortization charges	-	-	-	-
EBITDA	-22.97M	-28.03M	-32.64M	-34.86M
Gain or loss from assets sale	-	-	-	-

Finance